Gan Yi, Liu Zhihao, Tang Zhiwei, Yao Xiaojing, Zeng Bo, Zhu Haoshuai
Department of Thoracic Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510080, P.R. China.
Oncol Lett. 2023 Nov 6;26(6):546. doi: 10.3892/ol.2023.14133. eCollection 2023 Dec.
Preoperative neoadjuvant therapy is widely used in cancer treatment; however, its efficacy in different subtypes of non-small cell lung cancer (NSCLC) is unknown. The present study compared the clinical efficacy of preoperative neoadjuvant therapy for two major NSCLC subtypes. Patients with NSCLC who underwent preoperative neoadjuvant therapy between January 2016 and August 2022 were reviewed. Patients were stratified according to histology and treatment strategy. Retrospective analysis was performed by comparing the basic clinical characteristics of the patients, clinicopathological characteristics of the tumors, imaging data and pathological responses to treatment. A total of 36 cases of lung squamous cell carcinoma (LUSC) and 31 cases of lung adenocarcinoma (LUAD) were included. After neoadjuvant chemotherapy combined with immunotherapy, the pathological response rates were higher for patients with LUSC than LUAD, but there was no statistically significant difference between the two subgroups (P=0.06). However, the pathological complete response rates after neoadjuvant chemotherapy combined with immunotherapy were significantly higher for LUSC than those after chemotherapy alone (P=0.01). These preliminary findings suggested that preoperative chemotherapy combined with immunotherapy could improve the pathological response of patients, particularly in those with LUSC. The present study provided new insights into the treatment of NSCLC.
术前新辅助治疗在癌症治疗中被广泛应用；然而，其在非小细胞肺癌（NSCLC）不同亚型中的疗效尚不清楚。本研究比较了术前新辅助治疗对两种主要NSCLC亚型的临床疗效。回顾性分析了2016年1月至2022年8月期间接受术前新辅助治疗的NSCLC患者。根据组织学和治疗策略对患者进行分层。通过比较患者的基本临床特征、肿瘤的临床病理特征、影像学数据和治疗的病理反应进行回顾性分析。共纳入36例肺鳞状细胞癌（LUSC）患者和31例肺腺癌（LUAD）患者。新辅助化疗联合免疫治疗后，LUSC患者的病理反应率高于LUAD患者，但两组之间无统计学显著差异（P=0.06）。然而，新辅助化疗联合免疫治疗后的病理完全缓解率在LUSC患者中显著高于单纯化疗后（P=0.01）。这些初步研究结果表明，术前化疗联合免疫治疗可改善患者的病理反应，尤其是LUSC患者。本研究为NSCLC的治疗提供了新的见解。
